CO-DIAGNOSTICS, INC. Form 8-K Filing

Co-Diagnostics, Inc. has entered into an inducement agreement with holders of its existing warrants to purchase approximately 1.7 million shares of common stock. In exchange for exercising these warrants for cash, the company will issue new warrants to purchase approximately 3.4 million shares. The company anticipates receiving about $2.67 million in gross proceeds from the exercise of the existing warrants, before fees and expenses. Maxim Group LLC has been engaged as a placement agent for these transactions. The closing is expected around August 3, 2026, with proceeds intended for general corporate purposes. The company has also agreed to file a resale registration statement for the shares underlying the new warrants and has undertaken not to issue additional equity until August 31, 2026. A special stockholders' meeting will be convened to seek approval for the exercise of the new warrants. The new warrants will be exercisable for five years after stockholder approval, with provisions for cashless exercise if a resale registration statement is not effective.